ALXO — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• Our lease termination (gain) and impairment charge consists of a gain from lease termination and impairment of long-lived assets related to the Palo Alto lease.

• Our loss on debt extinguishment consists of a loss from the early extinguishment of the Oxford-SVB Loan.

• The following table summarizes our research and development (R&D) expenses incurred for the three months and six months ended June 30, 2026 and 2025 (in thousands):

• R&D expenses decreased by $4.9 million during the three months ended June 30, 2026 compared to the three months ended June 30, 2025. The decrease was primarily attributable to a decrease of $4.7 million in clinical and development costs primarily due to change in clinical development strategy reduci…

• R&D expenses decreased by $15.2 million during the six months ended June 30, 2026 compared to the six months ended June 30, 2025. The decrease was primarily attributable to a decrease of $7.0 million in clinical and development costs primarily due to change in clinical development strategy reducing …

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• The following table summarizes our results of operations for the three months ended March 31, 2026 and 2025 (in thousands):

• R&D expenses decreased by $10.3 million during the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The decrease was primarily attributable to a decrease of $4.4 million in personnel and related costs primarily driven by the reduction in workforce in early 2025, a…

• The following table summarizes our general and administrative (G&A) expenses incurred for the three months ended March 31, 2026 and 2025 (in thousands):

• G&A expenses decreased by $2.6 million during the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The decrease was primarily attributable to a decrease of $1.0 million in personnel and related costs primarily driven by the reduction in workforce in early 2025, a …

• Interest income decreased by $0.3 million for the three months ended March 31, 2026 compared to the three months ended March 31, 2025. The decreases were primarily attributable to lower interest rates during first quarter of 2026 as compared to first quarter of 2025.

Text added vs the prior filing · source: 10-Q · 2026-08-06

• In June 2026, the Company’s wholly-owned subsidiary, ALX Oncology Inc., entered into the HSBC Loan Agreement, under which we have borrowed $10.0 million. Under the HSBC Loan Agreement, we may draw up to an additional $20.0 million through June 30, 2028. A further $20.0 million is potentially availab…

• These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations. Further, there is currently significant uncertainty about the future relationship between the United States and various other countries, most signif…

• In addition, in February and April 2025, the current U.S. presidential administration imposed new tariffs on China and China responded with tariffs on select U.S. goods. While we cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China o…

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• In October 2022, we entered into the Loan Agreement, most recently amended in December 2023, under which we have borrowed $10.0 million. Under the Loan Agreement, $25.0 million is available for us to draw at the Lenders’ sole discretion as of March 31, 2026. The proceeds of the loans may be used by …

• These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations. Further, there is currently significant uncertainty about the future relationship between the United States and various other countries, most signif…